Dementia Therapeutic Pipeline Market by Companies & Drugs Profile Review H2 2014
Dallas, TX (PRWEB) December 06, 2014 -- The report "Dementia Pipeline Review H2 2014" provides comprehensive information on the therapeutic development for Dementia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dementia and special features on late-stage and discontinued projects. Dementia is the loss of psychological features such as considering, storage, and considering that is serious enough to intervene with a person's everyday performing. Complete Report is Available @ http://www.rnrmarketresearch.com/dementia-pipeline-review-h2-2014-market-report.html .
Companies discussed in this Dementia Pipeline Review H2 2014 report include Alector LLC, Biotie Therapies Corp., Bristol-Myers Squibb Company, Chase Pharmaceuticals Corporation, Chronos Therapeutics Limited, Echo Pharmaceuticals B.V., FORUM Pharmaceuticals Inc., Hyundai Pharmaceutical Co., Ltd., Ildong Pharmaceutical Co., Ltd., ImStar Therapeutics Inc., Integrative Research Laboratories Sweden AB, Intellect Neurosciences, Inc., Intra-Cellular Therapies, Inc., Oryzon Genomics S.A., Pacific Northwest Biotechnology, LLC, SK Chemicals Co., Ltd., Stelic Institute & Co., Summit Corporation plc, Sylentis S.A., Tautatis Incorporated, WhanIn Pharmaceutical Co., Ltd.
Drugs profile discussed in this Dementia Pipeline Review H2 2014 report include Antibodies for Dementia and Alzheimer's Disease, Antisense Oligonucleotide to Inhibit microRNA for Neurology, choline alfoscerate SR, CPC-252, dronabinol, Drugs to Agonize c-MET for Dementia, Drugs to Agonize c-MET for Dementia, FRM-0334, GIBH-130, gugulipid, IPN-007, IRL-752, ITI-007, KR-12, Monoclonal Antibodies to Inhibit Tau for CNS Disorders, NAT, NNC-269100, OG-635, Peptide to Inhibit BACE for Cerebropathy and Dementia, RDC-5, RNAi Oligonucleotide for Cerebral Ischemia and Dementia, SID-111, Small Molecule to Activate LPL for CNS and Metabolic Disorders, Small Molecule to Inhibit Glycogene 5 for Dementia, Small Molecule to Inhibit O-linked N-acetylglucosaminidase for Neurodegenerative Diseases, Synthetic Peptides for Neurological Disorders, TauC3 Monoclonal Antibody, TTT-3002 & WIB-1001C. Order a Purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=248269 .
Major points in Table of Content
List of Tables
Number of Products under Development for Dementia, H2 2014
Number of Products under Development for Dementia - Comparative Analysis, H2 2014
Number of Products under Development by Companies, H2 2014
Number of Products under Investigation by Universities/Institutes, H2 2014
Comparative Analysis by Clinical Stage Development, H2 2014
Comparative Analysis by Early Stage Development, H2 2014
Products under Development by Companies, H2 2014
Products under Development by Companies, H2 2014 (Contd..1)
Products under Investigation by Universities/Institutes, H2 2014
Dementia - Pipeline by Alector LLC, H2 2014
Dementia - Pipeline by Biotie Therapies Corp., H2 2014
Dementia - Pipeline by Bristol-Myers Squibb Company, H2 2014
Dementia - Pipeline by Chase Pharmaceuticals Corporation, H2 2014
Dementia - Pipeline by Chronos Therapeutics Limited, H2 2014
Dementia - Pipeline by Echo Pharmaceuticals B.V., H2 2014
Dementia - Pipeline by FORUM Pharmaceuticals Inc., H2 2014
Dementia - Pipeline by Hyundai Pharmaceutical Co., Ltd., H2 2014
Dementia - Pipeline by Ildong Pharmaceutical Co., Ltd., H2 2014
Dementia - Pipeline by ImStar Therapeutics Inc., H2 2014
Dementia - Pipeline by Integrative Research Laboratories Sweden AB, H2 2014
Dementia - Pipeline by Intellect Neurosciences, Inc., H2 2014
Dementia - Pipeline by Intra-Cellular Therapies, Inc., H2 2014
Dementia - Pipeline by Oryzon Genomics S.A., H2 2014
Dementia - Pipeline by Pacific Northwest Biotechnology, LLC, H2 2014
Dementia - Pipeline by SK Chemicals Co., Ltd., H2 2014
Dementia - Pipeline by Stelic Institute & Co., H2 2014
Dementia - Pipeline by Summit Corporation plc, H2 2014
Dementia - Pipeline by Sylentis S.A., H2 2014
Dementia - Pipeline by Tautatis Incorporated, H2 2014
Dementia - Pipeline by WhanIn Pharmaceutical Co., Ltd., H2 2014
Assessment by Monotherapy Products, H2 2014
Number of Products by Stage and Target, H2 2014
Number of Products by Stage and Mechanism of Action, H2 2014
Number of Products by Stage and Route of Administration, H2 2014
Number of Products by Stage and Molecule Type, H2 2014
Dementia Therapeutics - Recent Pipeline Updates, H2 2014
Dementia - Dormant Projects, H2 2014
Dementia - Dormant Projects (Contd..1), H2 2014
Dementia - Discontinued Products, H2 2014
Inquire before Buying @ http://www.rnrmarketresearch.com/contacts/inquire-before-buying?rname=248269 . (This is a premium report priced at US$2000 for a single user License.)
List of Figures
Number of Products under Development for Dementia, H2 2014
Number of Products under Development for Dementia - Comparative Analysis, H2 2014
Number of Products under Development by Companies, H2 2014
Number of Products under Investigation by Universities/Institutes, H2 2014
Comparative Analysis by Clinical Stage Development, H2 2014
Comparative Analysis by Early Stage Products, H2 2014
Assessment by Monotherapy Products, H2 2014
Explore more reports on Neurology therapeutics industry at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics/neurology-therapeutics .
About Us:
RnRMarketResearch.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.
Ritesh Tiwari, RnR Market Research, http://www.rnrmarketresearch.com/, +1 (888) 391-5441, [email protected]
Share this article